Vimarsana
Biggest News Aggregation in the World

Page 2 - Urologic Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Urologic Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Urologic Sciences Today - Breaking & Trending Today

PARP Inhibitors: Improving Outcomes in Metastatic Prostate Cancer - Vimarsana News

PARP Inhibitors: Improving Outcomes in Metastatic Prostate Cancer

Two new trials exploring this approach ― olaparib in the PROpel trial and niraparib in the MAGNITUDE trial –― had slightly different results.

AI helps researchers screen antiviral drugs to treat COVID-19 - Vimarsana News

AI helps researchers screen antiviral drugs to treat COVID-19

With AI, Dr. Artem Cherkasov and researchers took 19 days not 10 years to review 40 billion compounds to find potential COVID-19 drugs

Human studies begin on artificial Intelligence discovered COVID-19 treatment with up to 97 percent effectiveness - Vimarsana News

Human studies begin on artificial Intelligence discovered COVID-19 treatment with up to 97 percent effectiveness

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
iCo Therapeutics Subsidiary to present Oral Amphotericin B / | The Kingston Whig Standard - Vimarsana News

iCo Therapeutics Subsidiary to present Oral Amphotericin B / | The Kingston Whig Standard

Article content Vancouver, British Columbia–(Newsfile Corp. – May 11, 2021) – Amphotericin B Technologies, Inc (“Amp B Tech” or the “Company”), a wholly-owned subsidiary of iCo Therapeutics, Inc. (TSXV: ICO) (“iCo”), announced today that two presentations related to research on the effectiveness of the Company’s Oral Amphotericin B formulation (“iCo 019”) on the SARS-Cov-2 virus have been accepted to the 2021 CSPS/PSJ/CC-CRS Joint Symposium – Pharmaceutical Sciences in a Pandemic World. The Symposium will be held virtually from May 31 to June 3, 2021 and is sponsore...

iCo Therapeutics Inc.: iCo Therapeutics Subsidiary to present Oral Amphotericin B / SARS-Cov-2 Research Results at National Pharmaceutical Sciences Meeting - Vimarsana News

iCo Therapeutics Inc.: iCo Therapeutics Subsidiary to present Oral Amphotericin B / SARS-Cov-2 Research Results at National Pharmaceutical Sciences Meeting

(2) Vancouver, British Columbia--(Newsfile Corp. - May 11, 2021) - Amphotericin B Technologies, Inc ("Amp B Tech" or the "Company"), a wholly-owned subsidiary of iCo Therapeutics, Inc. (TSXV: ICO) ("iCo"), announced today that two presentations related to research on the effectiveness of the Company's Oral Amphotericin B formulation ("iCo 019") on the SARS-Cov-2 virus have been accepted to the 2021 CSPS/PSJ/CC-CRS Joint Symposium - Pharmaceutical Sciences in a Pandemic World. The Symposium will be held virtually from May 31 to June 3, 2021 and is sponsored by the Canadian Society for Pharma...